News
Remiges created our third seed stage company based on intellectual properties from the Japanese academia
04/01/2019
We are pleased to announce that the scientific discovery which forms the platform technology for Imel BioTherapeutics, one of our portfolio companies, was published in Scientific Reports on May 25th, 2021.
The discovery is about generation of somatic mitochondrial DNA replaced cells by the team at Kyoto Prefectural University of Medicine, led by Prof. Satoshi Gojo, the scientific founder of Imel BioTherapeutics, Inc.
The discovery is protected by patents globally and provides the firm's core platform technology to develop cell based therapy to treat diseases associated with inherited and acquired mtDNA mutations.